Business Context and Reporting Period
Syndax Pharmaceuticals Inc. filed this Form 8-K on October 17, 2017, reporting a material definitive agreement entered into on the same date. The company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
This filing details a registered direct offering of common stock rather than periodic financial performance results.
- Shares Issued: 2,021,018 shares of common stock.
- Price Per Share: $12.37.
- Net Proceeds: Approximately $24.8 million (after estimated expenses).
- Post-Offering Outstanding Shares: 24,389,929 shares.
- Underwriting: No underwriter or placement agent participated.
Material Changes
The primary material change is the increase in outstanding common stock and the influx of capital from the offering closed on October 20, 2017. The filing does not provide comparative financial data (revenue, profit, or cash flow) against prior periods.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure of the offering terms. The offering was conducted pursuant to a shelf registration statement declared effective on April 20, 2017.
Investor Verification Checklist
- Verify the final closing date of the offering (October 20, 2017) and the exact net proceeds received.
- Confirm the updated total share count of 24,389,929 shares outstanding.
- Review the Purchase Agreement (Exhibit 10.1) for any specific covenants or restrictions imposed by Biotechnology Value Fund, L.P.
- Check subsequent filings for the actual use of the approximately $24.8 million in proceeds.